Loading clinical trials...
Loading clinical trials...
A Retrospective and Prospective Study of a New Immunotherapy Regimen (MyVaccx) for Patients With Adenocarcinoma.
Conditions
Interventions
Immunotherapeutic Agents
Ablation
Locations
1
United States
The Center for High Risk and Recurrent Prostate Cancer
Fort Lauderdale, Florida, United States
Start Date
April 11, 2018
Primary Completion Date
July 8, 2019
Completion Date
June 17, 2020
Last Updated
July 22, 2020
NCT05691465
NCT06696768
NCT05198830
NCT05039801
NCT04704661
NCT04657068
Lead Sponsor
Gary Onik MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions